STMN1 and gastric cancer: It thus appeared initially that phospho-stathmin expression was correlated with nab-paclitaxel efficacy, lending some support to a hypothesis that phospho-stathmin can serve as a potential biomarker to predict nab-paclitaxel antitumor response in gastric cancer treatment.